RIPA-56

CAS No. 1956370-21-0

RIPA-56( RIPA56 | RIPA 56 )

Catalog No. M13064 CAS No. 1956370-21-0

A highly potent, selective, stable Receptor-interacting protein 1 (RIP1) inhibitor with IC50 of 13 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 29 Get Quote
10MG 43 Get Quote
25MG 77 Get Quote
50MG 124 Get Quote
100MG 203 Get Quote
200MG 300 Get Quote
500MG 503 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    RIPA-56
  • Note
    Research use only, not for human use.
  • Brief Description
    A highly potent, selective, stable Receptor-interacting protein 1 (RIP1) inhibitor with IC50 of 13 nM.
  • Description
    A highly potent, selective, stable Receptor-interacting protein 1 (RIP1) inhibitor with IC50 of 13 nM; shows good selectivity in kinase panel screening, and does not IDO activity ( at >200 uM); efficiently protects mice from mTNFα-induced multi-organ damage.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    RIPA56 | RIPA 56
  • Pathway
    Apoptosis
  • Target
    RIP kinase
  • Recptor
    RIP kinase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1956370-21-0
  • Formula Weight
    221.29546
  • Molecular Formula
    C13H19NO2
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    CCC(C)(C)C(N(O)CC1=CC=CC=C1)=O
  • Chemical Name
    Butanamide, N-hydroxy-2,2-dimethyl-N-(phenylmethyl)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ren Y, et al. J Med Chem. 2017 Feb 9;60(3):972-986.
molnova catalog
related products
  • CSLP43

    CSLP43 (RIPK2 inhibitor CSLP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay.

  • RIPK1-IN-4

    RIPK1-IN-4 is a potent and selective type II kinase receptor interacting protein 1 (RIP1) kinase inhibitor and binds to a DLG-out inactive form of RIP1 (IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase).

  • Sibiriline

    A specific competitive RIPK1 inhibitor with IC50 of 1.03 uM, 100-fold less potent for RIPK3.